Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Measuring the cost-effectiveness of vaccines targeting infectious diseases

Could your loyalty card help spot cancer? Study says yes

JP Morgan 2023 – Adi Hoess

Tackling ongoing staffing burnout rates through AI-enabled precision oncology

Ipsen’s rare disease drug palovarotene knocked back in EU

albuterol

astrazeneca-sign

Market Access/ News/ News/ News/ R&D

AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial

Eloise McLennan albuterol, asthma, Astra Zeneca, Avillion, budesonide 0 Comment

An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for

X

AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial

https://pharmaphorum.com/news/astrazeneca-avillion-first-in-class-combination-inhaler/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

Frontiers Health Steering Committee spotlight – Monique Levy

Frontiers Health Steering Committee spotlight – Monique Levy

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Most popular

Most Viewed

NICE recommends first CAR-T cell therapy on NHS in England
J&J copay lawsuit against drug benefit firm gets green light
ABPI code updated with first social media guidance
Could your loyalty card help spot cancer? Study says yes
Roche, Boehringer tap biosensor firms for patient studies

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2023

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com